J. Goldman & CO LP Apellis Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
A detailed history of J. Goldman & CO LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 283,153 shares of APLS stock, worth $5.76 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
283,153
Previous 93,574
202.6%
Holding current value
$5.76 Million
Previous $1.62 Million
295.74%
% of portfolio
0.19%
Previous 0.04%
Shares
7 transactions
Others Institutions Holding APLS
# of Institutions
330Shares Held
124MCall Options Held
4.15MPut Options Held
769K-
Avoro Capital Advisors LLC New York, NY12.2MShares$248 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$196 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$189 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8MShares$163 Million5.71% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...